Corporate Information

XOMA is a leader in the discovery, development and manufacture of therapeutic antibodies. XOMA's exceptionally broad technology platform, leading scientific expertise, and fully integrated product development infrastructure, extends from antibody discovery to regulatory approval. A proven development partner and technology licensor, XOMA receives royalties from UCB, S.A. for CIMZIA® (certolizumab pegol). Our pipeline includes an expanding number of proprietary products and collaborative programs at various stages of clinical and preclinical development.


Access XOMA 2009 Proxy Materials

Recent News

Mar 16, 2010

XOMA Receives Anticipated Notice of Non-Compliance From NASDAQ

Mar 14, 2010

XOMA 052 Prevents Adverse Cardiac Remodeling in Animal Model of Heart Attack

more »

Events

Mar 11, 2010

XOMA Ltd. Fourth Quarter 2009 Financial Results Conference Call

Mar 8, 2010

Cowen and Company 30th Annual Healthcare Conference

more »